Does the media refer more to DNLI or BEAM?

In the previous week, Beam Therapeutics had 5 more articles in the media than Denali Therapeutics. MarketBeat recorded 11 mentions for Beam Therapeutics and 6 mentions for Denali Therapeutics. Beam Therapeutics' average media sentiment score of 1.06 beat Denali Therapeutics' score of 1.01 indicating that Beam Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Denali Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Beam Therapeutics 7 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor ELAN or DNLI?

In the previous week, Elanco Animal Health had 3 more articles in the media than Denali Therapeutics. MarketBeat recorded 9 mentions for Elanco Animal Health and 6 mentions for Denali Therapeutics. Denali Therapeutics' average media sentiment score of 1.01 beat Elanco Animal Health's score of 0.72 indicating that Denali Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Elanco Animal Health 6 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Denali Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor AXSM or DNLI?

In the previous week, Axsome Therapeutics had 5 more articles in the media than Denali Therapeutics. MarketBeat recorded 11 mentions for Axsome Therapeutics and 6 mentions for Denali Therapeutics. Denali Therapeutics' average media sentiment score of 1.01 beat Axsome Therapeutics' score of 0.77 indicating that Denali Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Axsome Therapeutics 6 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Denali Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor ARWR or DNLI?

In the previous week, Arrowhead Pharmaceuticals had 17 more articles in the media than Denali Therapeutics. MarketBeat recorded 23 mentions for Arrowhead Pharmaceuticals and 6 mentions for Denali Therapeutics. Arrowhead Pharmaceuticals' average media sentiment score of 1.07 beat Denali Therapeutics' score of 1.01 indicating that Arrowhead Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arrowhead Pharmaceuticals 10 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Denali Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is ABVX or DNLI more profitable?

Denali Therapeutics' return on equity of -52.20% beat Abivax's return on equity. Company Net Margins Return on Equity Return on Assets Abivax N/A -99.02% -70.26% Denali Therapeutics N/A -52.20% -43.86%

Does the media favor ABVX or DNLI?

In the previous week, Abivax had 7 more articles in the media than Denali Therapeutics. MarketBeat recorded 13 mentions for Abivax and 6 mentions for Denali Therapeutics. Abivax's average media sentiment score of 1.41 beat Denali Therapeutics' score of 1.01 indicating that Abivax is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Abivax 12 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Denali Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Denali Therapeutics (DNLI) Competitors

$23.02 0.00 (0.00%)

Closing price 07/31/2026 04:00 PM Eastern

Extended Trading

$22.80 -0.22 (-0.96%)

As of 07/31/2026 07:34 PM Eastern

Compare

DNLI vs. BEAM, ELAN, AXSM, ARWR, and ABVX

Should you buy Denali Therapeutics stock or one of its competitors? MarketBeat compares Denali Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Denali Therapeutics include Beam Therapeutics (BEAM), Elanco Animal Health (ELAN), Axsome Therapeutics (AXSM), Arrowhead Pharmaceuticals (ARWR), and Abivax (ABVX).

How does Denali Therapeutics compare to Beam Therapeutics?

Denali Therapeutics (NASDAQ:DNLI) and Beam Therapeutics (NASDAQ:BEAM) are both mid-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, valuation, institutional ownership, analyst recommendations, earnings, risk, profitability and media sentiment.

In the previous week, Beam Therapeutics had 5 more articles in the media than Denali Therapeutics. MarketBeat recorded 11 mentions for Beam Therapeutics and 6 mentions for Denali Therapeutics. Beam Therapeutics' average media sentiment score of 1.06 beat Denali Therapeutics' score of 1.01 indicating that Beam Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Denali Therapeutics	4 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Beam Therapeutics	7 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Beam Therapeutics has lower revenue, but higher earnings than Denali Therapeutics. Beam Therapeutics is trading at a lower price-to-earnings ratio than Denali Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Denali Therapeutics	$330.53M	11.05	-$512.54M	-$2.88	N/A
Beam Therapeutics	$164.01M	16.01	-$79.99M	-$0.68	N/A

Denali Therapeutics currently has a consensus target price of $35.17, indicating a potential upside of 52.77%. Beam Therapeutics has a consensus target price of $46.85, indicating a potential upside of 83.57%. Given Beam Therapeutics' higher possible upside, analysts plainly believe Beam Therapeutics is more favorable than Denali Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Denali Therapeutics	1 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.75
Beam Therapeutics	1 Sell rating(s)	3 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.64

92.9% of Denali Therapeutics shares are owned by institutional investors. Comparatively, 99.7% of Beam Therapeutics shares are owned by institutional investors. 9.7% of Denali Therapeutics shares are owned by insiders. Comparatively, 3.8% of Beam Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Denali Therapeutics has a beta of 1.01, indicating that its share price is 1% more volatile than the broader market. Comparatively, Beam Therapeutics has a beta of 2.18, indicating that its share price is 118% more volatile than the broader market.

Denali Therapeutics has a net margin of 0.00% compared to Beam Therapeutics' net margin of -39.66%. Beam Therapeutics' return on equity of -29.00% beat Denali Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Denali Therapeutics	N/A	-52.20%	-43.86%
Beam Therapeutics	-39.66%	-29.00%	-22.61%

Summary

Beam Therapeutics beats Denali Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Denali Therapeutics compare to Elanco Animal Health?

Elanco Animal Health (NYSE:ELAN) and Denali Therapeutics (NASDAQ:DNLI) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, dividends, earnings, media sentiment, valuation, risk, analyst recommendations and institutional ownership.

Elanco Animal Health has a beta of 1.68, suggesting that its stock price is 68% more volatile than the broader market. Comparatively, Denali Therapeutics has a beta of 1.01, suggesting that its stock price is 1% more volatile than the broader market.

Denali Therapeutics has a net margin of 0.00% compared to Elanco Animal Health's net margin of -4.95%. Elanco Animal Health's return on equity of 7.42% beat Denali Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Elanco Animal Health	-4.95%	7.42%	3.66%
Denali Therapeutics	N/A	-52.20%	-43.86%

97.5% of Elanco Animal Health shares are held by institutional investors. Comparatively, 92.9% of Denali Therapeutics shares are held by institutional investors. 1.1% of Elanco Animal Health shares are held by company insiders. Comparatively, 9.7% of Denali Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Elanco Animal Health had 3 more articles in the media than Denali Therapeutics. MarketBeat recorded 9 mentions for Elanco Animal Health and 6 mentions for Denali Therapeutics. Denali Therapeutics' average media sentiment score of 1.01 beat Elanco Animal Health's score of 0.72 indicating that Denali Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Elanco Animal Health	6 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Denali Therapeutics	4 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Elanco Animal Health has higher revenue and earnings than Denali Therapeutics. Elanco Animal Health is trading at a lower price-to-earnings ratio than Denali Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Elanco Animal Health	$4.89B	2.70	-$232M	-$0.50	N/A
Denali Therapeutics	$330.53M	11.05	-$512.54M	-$2.88	N/A

Elanco Animal Health currently has a consensus price target of $28.73, indicating a potential upside of 8.72%. Denali Therapeutics has a consensus price target of $35.17, indicating a potential upside of 52.77%. Given Denali Therapeutics' higher possible upside, analysts plainly believe Denali Therapeutics is more favorable than Elanco Animal Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Elanco Animal Health	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.77
Denali Therapeutics	1 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.75

Summary

Elanco Animal Health beats Denali Therapeutics on 10 of the 17 factors compared between the two stocks.

How does Denali Therapeutics compare to Axsome Therapeutics?

Axsome Therapeutics (NASDAQ:AXSM) and Denali Therapeutics (NASDAQ:DNLI) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, media sentiment, profitability, institutional ownership, earnings and risk.

Axsome Therapeutics has higher revenue and earnings than Denali Therapeutics. Axsome Therapeutics is trading at a lower price-to-earnings ratio than Denali Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Axsome Therapeutics	$638.50M	17.57	-$183.17M	-$3.73	N/A
Denali Therapeutics	$330.53M	11.05	-$512.54M	-$2.88	N/A

81.5% of Axsome Therapeutics shares are owned by institutional investors. Comparatively, 92.9% of Denali Therapeutics shares are owned by institutional investors. 20.6% of Axsome Therapeutics shares are owned by insiders. Comparatively, 9.7% of Denali Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Denali Therapeutics has a net margin of 0.00% compared to Axsome Therapeutics' net margin of -26.59%. Denali Therapeutics' return on equity of -52.20% beat Axsome Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Axsome Therapeutics	-26.59%	-267.16%	-28.53%
Denali Therapeutics	N/A	-52.20%	-43.86%

Axsome Therapeutics presently has a consensus target price of $261.29, indicating a potential upside of 19.86%. Denali Therapeutics has a consensus target price of $35.17, indicating a potential upside of 52.77%. Given Denali Therapeutics' higher probable upside, analysts plainly believe Denali Therapeutics is more favorable than Axsome Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Axsome Therapeutics	2 Sell rating(s)	0 Hold rating(s)	19 Buy rating(s)	2 Strong Buy rating(s)	2.91
Denali Therapeutics	1 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.75

Axsome Therapeutics has a beta of 0.65, meaning that its share price is 35% less volatile than the broader market. Comparatively, Denali Therapeutics has a beta of 1.01, meaning that its share price is 1% more volatile than the broader market.

In the previous week, Axsome Therapeutics had 5 more articles in the media than Denali Therapeutics. MarketBeat recorded 11 mentions for Axsome Therapeutics and 6 mentions for Denali Therapeutics. Denali Therapeutics' average media sentiment score of 1.01 beat Axsome Therapeutics' score of 0.77 indicating that Denali Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Axsome Therapeutics	6 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Denali Therapeutics	4 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Axsome Therapeutics beats Denali Therapeutics on 9 of the 17 factors compared between the two stocks.

How does Denali Therapeutics compare to Arrowhead Pharmaceuticals?

Arrowhead Pharmaceuticals (NASDAQ:ARWR) and Denali Therapeutics (NASDAQ:DNLI) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, earnings, dividends, risk and media sentiment.

Arrowhead Pharmaceuticals has higher revenue and earnings than Denali Therapeutics. Arrowhead Pharmaceuticals is trading at a lower price-to-earnings ratio than Denali Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arrowhead Pharmaceuticals	$829.45M	14.38	-$1.63M	-$2.15	N/A
Denali Therapeutics	$330.53M	11.05	-$512.54M	-$2.88	N/A

62.6% of Arrowhead Pharmaceuticals shares are held by institutional investors. Comparatively, 92.9% of Denali Therapeutics shares are held by institutional investors. 3.6% of Arrowhead Pharmaceuticals shares are held by company insiders. Comparatively, 9.7% of Denali Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Denali Therapeutics has a net margin of 0.00% compared to Arrowhead Pharmaceuticals' net margin of -48.38%. Denali Therapeutics' return on equity of -52.20% beat Arrowhead Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arrowhead Pharmaceuticals	-48.38%	-55.09%	-18.13%
Denali Therapeutics	N/A	-52.20%	-43.86%

In the previous week, Arrowhead Pharmaceuticals had 17 more articles in the media than Denali Therapeutics. MarketBeat recorded 23 mentions for Arrowhead Pharmaceuticals and 6 mentions for Denali Therapeutics. Arrowhead Pharmaceuticals' average media sentiment score of 1.07 beat Denali Therapeutics' score of 1.01 indicating that Arrowhead Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arrowhead Pharmaceuticals	10 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Denali Therapeutics	4 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Arrowhead Pharmaceuticals has a beta of 1.27, meaning that its stock price is 27% more volatile than the broader market. Comparatively, Denali Therapeutics has a beta of 1.01, meaning that its stock price is 1% more volatile than the broader market.

Arrowhead Pharmaceuticals currently has a consensus price target of $96.92, indicating a potential upside of 14.49%. Denali Therapeutics has a consensus price target of $35.17, indicating a potential upside of 52.77%. Given Denali Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Denali Therapeutics is more favorable than Arrowhead Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arrowhead Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.62
Denali Therapeutics	1 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.75

Summary

Arrowhead Pharmaceuticals and Denali Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

How does Denali Therapeutics compare to Abivax?

Abivax (NASDAQ:ABVX) and Denali Therapeutics (NASDAQ:DNLI) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, analyst recommendations, dividends, media sentiment, institutional ownership, earnings, risk and valuation.

Abivax presently has a consensus price target of $156.50, indicating a potential upside of 25.28%. Denali Therapeutics has a consensus price target of $35.17, indicating a potential upside of 52.77%. Given Denali Therapeutics' higher possible upside, analysts clearly believe Denali Therapeutics is more favorable than Abivax.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Abivax	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.80
Denali Therapeutics	1 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.75

In the previous week, Abivax had 7 more articles in the media than Denali Therapeutics. MarketBeat recorded 13 mentions for Abivax and 6 mentions for Denali Therapeutics. Abivax's average media sentiment score of 1.41 beat Denali Therapeutics' score of 1.01 indicating that Abivax is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Abivax	12 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Denali Therapeutics	4 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Abivax has higher earnings, but lower revenue than Denali Therapeutics. Abivax is trading at a lower price-to-earnings ratio than Denali Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Abivax	N/A	N/A	-$380.27M	-$5.21	N/A
Denali Therapeutics	$330.53M	11.05	-$512.54M	-$2.88	N/A

Abivax has a beta of 1.03, meaning that its share price is 3% more volatile than the broader market. Comparatively, Denali Therapeutics has a beta of 1.01, meaning that its share price is 1% more volatile than the broader market.

Denali Therapeutics' return on equity of -52.20% beat Abivax's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Abivax	N/A	-99.02%	-70.26%
Denali Therapeutics	N/A	-52.20%	-43.86%

47.9% of Abivax shares are held by institutional investors. Comparatively, 92.9% of Denali Therapeutics shares are held by institutional investors. 9.7% of Denali Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Denali Therapeutics beats Abivax on 8 of the 13 factors compared between the two stocks.

Get Denali Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DNLI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

DNLI vs. The Competition

Export

Metric	Denali Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$3.65B	$3.54B	$6.86B	$12.42B
Dividend Yield	N/A	3.78%	2.59%	10.03%
P/E Ratio	-7.99	7.38	282.30	24.66
Price / Sales	11.05	1,201.52	564.98	76.51
Price / Cash	N/A	44.80	28.60	46.71
Price / Book	3.33	16.78	10.92	6.07
Net Income	-$512.54M	-$12.56M	$3.49B	$347.99M
7 Day Performance	-2.33%	-1.79%	-0.64%	-0.44%
1 Month Performance	-10.88%	-8.41%	-5.24%	-4.81%
1 Year Performance	71.28%	48.37%	61.98%	18.61%

Denali Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
DNLI Denali Therapeutics	2.8211 of 5 stars	$23.02 flat	$35.17 +52.8%	+71.3%	$3.65B	$330.53M	N/A	430	Positive News Upcoming Earnings Gap Up
BEAM Beam Therapeutics	2.5419 of 5 stars	$25.07 -0.1%	$46.85 +86.9%	+35.5%	$2.58B	$164.01M	N/A	510	Positive News Upcoming Earnings
ELAN Elanco Animal Health	2.9495 of 5 stars	$25.48 +2.3%	$28.73 +12.7%	+91.5%	$12.44B	$4.89B	N/A	9,400	Positive News Upcoming Earnings Analyst Upgrade
AXSM Axsome Therapeutics	3.3115 of 5 stars	$238.37 -1.1%	$261.48 +9.7%	+111.6%	$12.40B	$638.50M	N/A	380	Upcoming Earnings Analyst Forecast Gap Up
ARWR Arrowhead Pharmaceuticals	2.33 of 5 stars	$85.53 -0.1%	$95.08 +11.2%	+431.4%	$12.06B	$829.45M	N/A	400	Positive News Upcoming Earnings Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:DNLI) was last updated on 8/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Denali Therapeutics (DNLI) Competitors

DNLI vs. BEAM, ELAN, AXSM, ARWR, and ABVX

How does Denali Therapeutics compare to Beam Therapeutics?

Summary

How does Denali Therapeutics compare to Elanco Animal Health?

Summary

How does Denali Therapeutics compare to Axsome Therapeutics?

Summary

How does Denali Therapeutics compare to Arrowhead Pharmaceuticals?

Summary

How does Denali Therapeutics compare to Abivax?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DNLI vs. The Competition

Denali Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Denali Therapeutics (DNLI) Competitors

DNLI vs. BEAM, ELAN, AXSM, ARWR, and ABVX

How does Denali Therapeutics compare to Beam Therapeutics?

Does the media refer more to DNLI or BEAM?

Which has stronger earnings and valuation, DNLI or BEAM?

Do analysts prefer DNLI or BEAM?

Do insiders and institutionals have more ownership in DNLI or BEAM?

Which has more risk & volatility, DNLI or BEAM?

Is DNLI or BEAM more profitable?

Summary

How does Denali Therapeutics compare to Elanco Animal Health?

Which has more risk & volatility, ELAN or DNLI?

Is ELAN or DNLI more profitable?

Do institutionals & insiders believe in ELAN or DNLI?

Does the media favor ELAN or DNLI?

Which has better valuation & earnings, ELAN or DNLI?

Do analysts recommend ELAN or DNLI?

Summary

How does Denali Therapeutics compare to Axsome Therapeutics?

Which has better valuation and earnings, AXSM or DNLI?

Do institutionals and insiders believe in AXSM or DNLI?

Is AXSM or DNLI more profitable?

Do analysts prefer AXSM or DNLI?

Which has more volatility and risk, AXSM or DNLI?

Does the media favor AXSM or DNLI?

Summary

How does Denali Therapeutics compare to Arrowhead Pharmaceuticals?

Which has higher valuation & earnings, ARWR or DNLI?

Do institutionals & insiders believe in ARWR or DNLI?

Is ARWR or DNLI more profitable?

Does the media favor ARWR or DNLI?

Which has more risk & volatility, ARWR or DNLI?

Do analysts prefer ARWR or DNLI?

Summary

How does Denali Therapeutics compare to Abivax?

Do analysts rate ABVX or DNLI?

Does the media favor ABVX or DNLI?

Which has preferable earnings and valuation, ABVX or DNLI?

Which has more risk and volatility, ABVX or DNLI?

Is ABVX or DNLI more profitable?

Do insiders & institutionals believe in ABVX or DNLI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DNLI vs. The Competition

Denali Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools